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Abstract Headache is being viewed more commonly in a
biopsychosocial framework, which introduces the possible
utilisation of psychological treatment options, such as
cognitive behavioural therapy and relaxation. No such
treatments have been trialled in the UK. We conducted a
randomised controlled pilot trial, comparing a brief guided
self-help CBT and relaxation treatment with standard
medical care (SMC), in a UK NHS setting. Participants
were recruited from specialist headache clinics across
London. Participants were randomised to receive either
treatment or standard medical care. Our objective was to
provide design information necessary for a future definitive
trial of the SHE treatment, including, recruitment/retention
rates, acceptability of randomisation, treatment fidelity and
estimations of mean and variances of outcome measures.
From the initial 275 patients identified, 73 were ran-
domised. There was no difference in drop-out rates
between SMC and treatment groups. Of the 36 participants
randomised to receive treatment, 72 % attended all ses-
sions. Findings show that a future definitive trial of the
SHE treatment is feasible, with small modifications of
protocol, within a UK NHS context.
Keywords Migraine  Cognitive behavioural therapy 
Relaxation  Headache
Introduction
Migraine headache is the third most prevalent condition [1]
and seventh highest among specific causes of disability,
globally [2, 3]. In the UK, 18 % of women and 8 % of men
suffer from migraine [4]. Personal, social and work life can
be severely affected [5], with quality of life, both during
and between attacks, substantially reduced [6]. Service and
social costs are also high, and increase with symptom
severity [7].
Current standard treatment for migraine headache is
medication [8]. However, high levels of psychological
comorbidity [9] has led to migraine becoming more com-
monly viewed as a biopsychosocial condition [10], influ-
enced by cognitive, emotional and environmental factors,
as well as biological. Of the 4 % of people who consult
their family doctor for headache, 28 % have clinically
significant levels of anxiety or depression [11]. Headache is
the most common reason for referral to neurology [12],
with those referred showing higher levels of anxiety about
their headache symptoms and consulting more frequently
than patients managed in primary care [11]. Lifestyle fac-
tors, such as stress and sleep quality, can contribute sig-
nificantly to onset and course of headaches, and
management of these factors, including identification of
environmental triggers, is increasingly important in the
treatment of migraine. Viewing headache in a biopsy-
chosocial framework introduces the possible utilisation of
psychological treatment options, such as cognitive beha-
vioural therapy (CBT), relaxation and biofeedback. These
treatments allow patients to develop preventative and acute
management strategies, such as trigger identification,
modification of maladaptive inter-related thoughts, feelings
and behaviours surrounding headache, as well as physio-
logical auto-regulation strategies. Reviews of randomised
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controlled trials assessing the effectiveness of behavioural
treatments found a 32 % reduction in headache frequency
compared to 5 % in controls [13]. Furthermore, Holroyd
et al. [14] found that combining a behavioural treatment
programme with prophylactic drug treatment was more
effective in reducing migraine frequency than either of the
two treatments presented on their own. Relaxation and
CBT treatments when delivered separately have been
found to show similar effectiveness in treating headache
[15], and minimal contact [3, 4] sessions, combined with
written material and audiotapes, can achieve outcomes as
good as more intensive and expensive treatments [16, 17].
The effectiveness of psychological treatments has been
shown primarily by studies carried out in the United States
and in some European countries (US) [15, 16]. In the US
health systems, heavy reliance on private insurance funding
and likely cost barriers to recruitment to this treatment limits
the generalizability of these studies. Even in countries where
universal care has been provided for many years, the popu-
lation profile and systems of delivery are different, making it
difficult to generalise findings from complex interventions.
The United Kingdom’s (UK) National Health Service
(NHS), a publically funded health system, provides universal
access in principle to all socio-economic groups [18]. No
such treatments have been developed and tested in the UK,
tailored to the NHS context. In the context of this research
gap, the UK’s National Institute for Health and Care
Excellence (NICE) called for studies investigating the
effectiveness of psychological treatments for headache [8].
Currently, it is unknown whether a full RCT assessing a
non-drug psychological treatment for headache would suc-
ceed in terms of recruitment and retention rates in the UK.
MRC guidelines for developing and evaluating complex
interventions highlight the importance of the piloting of
complex interventions and warn against a focus solely on
evaluation, to the detriment of adequate development and
pilot work [19]. Indeed, only 1 in 3 MRC and NIHR trials
have been found to recruit their target sample in time [20],
underlining the need for pilot trials that provide insight into
the ability to recruit and retain participants, as well as
increasing the likelihood of a high-quality definitive RCT.
In line with MRC guidelines, we conducted a pilot trial
to provide design information necessary for a future
definitive RCT, which could assess the effectiveness of the
SHE treatment. We were informed by Lancaster et al. [21]
in defining our objectives. As recommended, the signifi-
cance of treatment effect was not assessed in this pilot
study. Our pilot trial objectives were i) to calculate
recruitment, consent and follow-up rates, ii) to test
acceptability of randomisation to participants, iii) to assess
treatment fidelity of SHE, and iv) to provide estimates of
the mean and standard deviation of the outcomes measures
to inform future sample size calculation.
Method
Participants were recruited from specialist headache clinics
(neurologists and family doctors with a special interest in
headache) across London. Participants who expressed an
interest in the study were invited to undergo a screening
assessment. Inclusion criteria were adults (men and
women) aged 18–75 years; diagnosis of migraine head-
ache; onset[6 months previously; and[3 headache days
per month (assessed by headache diary; including both
episodic and chronic migraine). Exclusion criteria were
physical conditions likely to cause headache (secondary
headache); pregnancy; current psychotic illness; substance
dependency (not including headache rescue medication);
currently undergoing psychological therapy; and inability
to complete self-report measures. Patients were recruited
according to the criteria available at the time which was the
HIS classification guidelines (2nd Edition). Patients with
migraine without and with auras were included. Additional
diagnosis of medication overuse headache was not an
exclusion criterion. Suitable participants completed out-
come measures at a baseline (face-to-face) assessment,
carried out either at the participants’ home or the research
site, and were then randomised to SMC or treatment (plus
SMC) groups. Trialists waited until any changes to pro-
phylactic medication had been implemented and stabilised
before recruitment. Participants were followed up at 2 and
4 months and were given a £20 shopping voucher on
completion of the final follow-up assessment. Ethical
approval was obtained from South East London regional
ethics committee (10/H0805/79) and informed consent was
obtained from all participants. The trial is ISRCTN regis-
tered (ISRCTN53460881) and is on the UK Clinical
Research Network Study Portfolio (UKCRN ID 11265).
Treatment
The treatment combines CBT and relaxation (deep
breathing and progressive muscle relaxation) training in a
minimal contact manualised intervention, carried out over
5 weeks in three face-to-face sessions, alternating with two
telephone calls. The treatment was delivered by one trained
[Improving Access to Psychological Therapies (IAPT)]
CBT therapist. The therapist received a therapist’s manual
(available from LR), containing details regarding delivery
and content of the treatment, and underwent bi-weekly
supervision sessions with a senior CBT therapist SM. The
therapists’ manual was previously developed by LR, and
feedback from users incorporated. Participants were given
a copy of a patient manual, developed and structured to be
used alongside and add to the therapy sessions. Session 1
(week 1) introduced the concept of links between thoughts,
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feelings, symptoms and behaviours, thought monitoring
and relaxation techniques. Participants were given head-
ache and thought diaries to complete at home and were
asked to practice relaxation techniques (with an accom-
panying CD) for approximately 15 min each day (record-
ing levels of tension before and after). Session 2 (week 3)
introduced problem solving and cognitive restructuring
techniques, including alternative thinking. Session 3 (week
5) built on alternative thinking techniques and covered
relapse prevention. Thought and headache diaries were
reviewed in sessions 2 and 3, and phone calls (weeks 2 and
4) were used to review practice and identify any difficul-
ties. The patient manual includes an educational compo-
nent where patients are given information about what
migraine is, medication, as well as informing them about
identifying and managing triggers, including stress. The
average duration of face-to-face sessions was 63 min
(range 34–96). Participants randomised to the SMC con-
tinued treatment as usual with no restrictions, and received
the patient handbook in the post after the final follow-up
assessment.
Fidelity measure
On the basis of the therapist and patient manuals, a
checklist of treatment components was devised. Eight rat-
ing scales (1 = very poor to 7 = excellent) assessing
therapeutic skill (e.g. supportive encouragement, commu-
nication style, overall therapeutic alliance) were also
included. Two CBT therapists unconnected with the trial
completed the fidelity measure. They were given audio-
recordings of 30 randomly selected face-to-face treatment
sessions (n = 10 each of sessions 1, 2 and 3), and asked to
identify whether each treatment component was present in
the session and rate the level of therapeutic skill on each of
the 8 rating scales. The fidelity measure was piloted on two
randomly selected sessions to clarify the meaning of indi-
vidual items and for raters to improve the clarity of coding
instructions.
Outcome measures
All outcome measures (self-report questionnaires) were
completed at baseline and four months (primary end-point).
In order to enhance retention, participants also carried out a
shortened assessment at 2 months, by post. Primary out-
come measure was number of headache days, assessed by
headache diary completed during the months (28 days)
immediately preceding baseline and four-month follow-
ups. Participants were asked to record in the diary the date,
duration and pain intensity (0 = no pain, to 10 = worst
possible pain) of each headache experienced, as well as any
rescue medications taken at the time of the headache. A
headache day was defined as a day containing 2 or more
hours of headache. Secondary outcome measures included
Migraine Disability Assessment (MIDAS) [22], assessing
migraine related disability, a higher score reflecting more
severe disability ([21 = severe disability); Headache
Impact Test [23] (HIT-6), assessing the impact of head-
ache, score range is 36–78, with a higher score reflecting
higher impact; Hospital Anxiety and Depression Scale
(HADS) [24], a state-based measure of anxiety and
depression, where for each subscale a score of C11 shows
probable presence of a mood disorder [25]; Brief Illness
Perceptions Questionnaire (B-IPQ) [26], assessing the
degree to which headaches are perceived as threatening or
benign, a higher score reflects a more threatening view of
headache; and EuroQol (EQ-5D) [27], assessing health-
related quality of life across five dimensions (mobility,
self-care, usual activities, pain/discomfort, anxiety/
depression).
Randomisation and blinding
Randomisation was carried out using a web-based Inde-
pendent Randomisation Service provided by King’s
College London, Clinical Trials Unit (KCL, CTU). The
researcher requested randomisation by logging in with a
unique username and password, and entering coded
participant details. Participants were allocated to either
SMC or treatment group using this system. Emails were
automatically generated and sent to the researcher
(blinded) confirming randomisation and to the therapist
(unblinded) giving randomisation details. The randomi-
sation method used was minimisation, with minimisation
factor—frequency of headache days (1. B14 headache
days per month 2. C15 headache days per month).
Participant assessments and data entry were carried out
by a researcher (SC) blinded to treatment allocation. At
assessments and during treatment sessions (if in treatment
group) participants were actively reminded that the
researcher should not be made aware of treatment alloca-
tion. Outcome measure data were entered by the researcher
into the Online Data Capture and Management Service,
MACRO database (developed by Infermed, provided by
KCL CTU), which is able to securely capture data online,
via bespoke electronic case report forms. For the purposes
of analysis, the researcher was unblinded once the data for
all follow-ups had been securely entered to the MACRO
system.
Sample size calculation
We considered that 30 patients in each arm of the study
would provide estimates of the properties of the main
2766 J Neurol (2015) 262:2764–2772
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outcome measure with adequate precision to be able to
calculate the sample size needed for a definitive trial. Sixty
participants would allow estimation of the standard devi-
ation (SD) to within 20 % of the true value (based on the
Chi-square distribution). The use of the upper one-sided
80 % interval guarded against the study failing due to
inadequate power at a cost of only a 16 % greater sample
size. The correlation between repeated measures can like-
wise be estimated to within under 0.1 units of the true value
(upper one-sided 80 % interval). Estimating a 15–25 %
drop-out rate at 6 months, we therefore planned to recruit
40 patients in each arm to allow for possible discontinua-
tion, making 80 patients in total.
Statistical analysis
We calculated key information relating to our objectives,
including, uptake, eligibility, recruitment and retention
Fig. 1 Diagram showing
participant flow through the
study. Excluded after screening
assessment—‘other’ reasons
include personal reasons
(n = 4); pursuing other
treatment (n = 3); relocation
(n = 1); health reasons (n = 2);
unstable medication (n = 2); no
reason given (n = 1). ‘Did not
meet inclusion criteria’ reasons
include insufficient headache
days (n = 7), abnormal MRI
scan (n = 2), in psychological
therapy (n = 1)
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rates, and treatment attendance. Baseline demographics
were compared between completer and non-completer
groups using independent samples t-tests and Chi-square
tests for categorical variables. All analyses were based on
the intention to treat principle.
Results
Participant recruitment and retention
Figure 1 illustrates participant flow through the study.
From the initial 275 patients identified, between August
2012 and March 2014, 120 consented to a screening
assessment and 73 participants were then fully recruited
into the trial. These participants completed a baseline
assessment and were randomised to receive either SMC
(n = 37) or the treatment (n = 36). At baseline assess-
ment, the two groups (SMC and treatment) were similar
(Table 1).
Fifty-six (76.71 %) participants completed the final
four-month follow-up assessment, 27 in the SMC group
and 29 participants in the treatment group. Intention to treat
analysis was conducted on these participants who had
completed the final 4-month follow-up assessment,
regardless of receipt of treatment. Primary outcome
(Number of headache days) data were obtained for 25
participants in the SMC group and 28 participants in the
treatment group and (n = 2 and 1, respectively, excluded
due to incomplete headache diary). Secondary outcome
measures were completed by all participants followed up at
the 4-month follow-up (Fig. 2).
The overall loss to final follow-up was 17 (23.29 %), 10
in the SMC group and 7 participants in the treatment group.
The loss to follow-up was not significantly different
between groups (X2(1) = 0.59, p = 0.44). Table 2 shows
no significant difference in the baseline characteristics
between completers and non-completers, although there
was a trend for non-completers to score higher on the
headache-related disability measures at baseline.
Unblinding
Unblinding occurred for 22 of the 73 (30.1 %) participants.
The majority (n = 17) occurred for participants in the
treatment group due to, for example, the blinded researcher
being contacted about treatment (n = 10). Five instances
of unblinding occurred in the SMC group with reasons
including, participants’ expression of dissatisfaction with
treatment group allocation, and communication from a
participant regarding receiving the treatment handbook in
the post after final follow-up.
Table 1 Baseline measures for SMC and Treatment groups
Baseline measures ALL SMC
(n = 37)
Treatment
(n = 36)
Difference
(SMC vs
intervention)
95 % confidence
interval
Lower Upper
Gender
Female (%) 60 (82.2) 32 (86.5) 28 (77.8)
Male (%) 13 (17.8) 5 (13.5) 8 (22.2)
Age (range, years), sd 39 (19–71) 37.97 (19–71), 12.04 40.67 (19–70), 12.79 2.70 -2.61 3.96
Ethnicity
Asian (%) 1 (1.4) 0 (0) 1 (2.8)
Black (%) 12 (16.4) 9 (24.3) 3 (8.3)
White (%) 53 (72.6) 24 (64.9) 29 (80.6)
Mixed (%) 5 (6.8) 2 (5.4) 3 (8.3)
Other (%) 1 (1.4) 1 (2.7) 0 (0)
Mean diary headache days (sd) 11.780 (7.67) 11.54 (6.64) 12.03 (8.70) 0.49 -0.43 3.67
Mean number of days rescue
medication used in diary month (sd)
6.89 (5.55) 7.08 (5.87)a 6.69 (5.30) -0.39 0.43 3.39
MIDAS, mean score (sd) 58.51 (45.57) 65.78 (46.79) 51.023 (43.68) -14.75 15.08 39.00
HIT-6, mean score (sd) 66.23 (5.16) 65.97 (4.41) 66.5 (5.88) 0.53 -0.49 2.26
HADS-anxiety, mean score (sd) 8.56 (3.84) 9.32 (3.55) 7.78 (4.01) -1.54 1.57 3.57
HADS-depression, mean score (sd) 5.75 (3.89) 5.68 (3.09) 5.83 (4.61) 0.15 -0.12 1.96
Brief-IPQ, mean score (sd) 52.10 (9.69) 51.41 (9.77) 52.81 (9.69) 1.40 -1.33 3.82
a n 1 missing data, MIDAS migraine disability assessment scale, HIT-6 headache impact test, HADS-A hospital anxiety and depression scale,
Anxiety subscale, HADS-D hospital anxiety and depression scale, depression subscale, Brief-IPQ Brief Illness Perceptions Questionnaire
2768 J Neurol (2015) 262:2764–2772
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Adherence to treatment protocol
Of the n = 36 patients randomly assigned to receive the
intervention, 26 (72.2 %) completed all five sessions. Two
patients (5.6 %) did not attend any sessions, 3 (8.3 %)
completed one session, 1 (2.8 %) completed two sessions,
1 (2.8 %) completed three sessions and 3 (8.3 %) partici-
pants completed four sessions.
Fidelity measure
An average (across raters) of 84 % of components identi-
fied in the fidelity checklist were rated as being present by
the two raters, in the 30 sessions sampled; session 1—16/
17 components present, session 2—9/11 components pre-
sent, session 3—12/14 components present. The average
rating of overall therapeutic reliance across both raters and
all sessions was 5 (good).
Sample size calculation—future definitive trial
Table 3 shows means and variances for all outcome mea-
sures, for treatment and SMC groups at baseline and
4-month follow-up. Based on this data, we estimate the
effect of the treatment on the main outcome as between
-3.2 and ?2.4 headache days. We also observed a stan-
dard deviation of 6.76, and a correlation of 0.67 between
baseline and final outcome. Complete data on 133 patients
per group (266 in all) would give 90 % power to detect
such a treatment effect. Assuming 76.7 % completion rate
(as in the pilot), 347 participants would need to be
recruited. The upper 95 % limit for the standard deviation
is 8.37. Using this conservative approach about the true SD
value, complete data on 203 participants per group (406 in
all) would be needed for 90 % power, implying 529 par-
ticipants to be recruited.
Discussion
This is the first UK-based pilot trial of a minimal contact
CBT with relaxation treatment for migraine headache.
Findings show adequate recruitment and good treatment
adherence. This pilot study did not aim, nor was it powered
sufficiently, to comment on the effectiveness of the treat-
ment; however, our results show that a future definitive
trial in the UK is feasible.
With regard to patient recruitment, it was originally
assumed that 75 % of patients identified would decline
participation; our recruitment rates show that of the 275
patients identified, 44 % agreed to undergo a screening
assessment and 61 % of those participants screened were
consented into the trial. Inability to contact patients after
their initial expression of interest was the main reason for
patient exclusion before screening, and this may be reduced
in a future trial by incorporating the screening assessment
into the initial meeting with patients.
Fig. 2 Figure showing timeline
and components of the
behavioural therapy and
relaxation treatment
J Neurol (2015) 262:2764–2772 2769
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Participant adherence to treatment was good. Over 70 %
of participants randomised to the treatment group com-
pleted all five treatment sessions, with only two partici-
pants not attending any sessions.
Participant drop-out rates did not differ between treat-
ment and SMC groups, suggesting that participants
accepted randomisation well; however, one participant was
unhappy that they had not received treatment and had been
allocated to the SMC group, and refused further data
collection.
Treatment fidelity
The fidelity measure and therapeutic alliance scale devel-
oped herewith provides a valuable verification of whether
treatment is delivered as intended [28], and also enables the
evaluation of the role of process factors in predicting out-
come. Accurate monitoring of treatment fidelity can
increase the internal and external validity of the treatment,
allowing more accurate conclusions regarding treatment
efficacy in a future definitive trial [29].
Adherence to the treatment protocol may be maximised
by ongoing training of those delivering the treatment.
Therapists may also be asked to complete treatment com-
ponent checklists after each session. The application of
these fidelity strategies in a future definitive trial, in addi-
tion to treatment manuals, can maximise standardisation of
treatment delivery [28].
Limitations and future trial considerations
The current study was not double-blinded; it was not
possible to blind the participants or the therapist delivering
the treatment to treatment group allocation and partici-
pants, once aware of whether they are receiving treatment
or not, may value their outcomes differently [30]. This is a
common limitation in behavioural intervention RCTs [30]
due to the lack of suitable inactive control options. The
single-blinding of the researcher collecting outcome data
was moderately successful. Accidental unblinding may be
reduced in a future trial by—(i) outcome measures being
completed through an online or postal submission process,
rather than face-to-face, (ii) different researchers under-
taking assessments and inputting data, (iii) employment of
an unblinded researcher to answer participant and clinician
queries, as well as help in the implementation of any nested
qualitative studies. These changes would limit the inter-
actions between participants and those researchers assess-
ing outcomes and may reduce accidental unblinding.
Participant dissatisfaction with control group allocation
Table 2 Baseline measures in completer and non-completer groups
Baseline measures Completers of 4-month
assessment (n = 56)
Non-completers of
4-month assessment
(n = 17)
Difference
(completers vs
non-completers)
95 % confidence
interval
t p
Lower Upper
Gender
Female (%) 46 (82.1) 14 (82.4) 0.98
Male (%) 10 (17.9) 3 (17.6)
Age (range, years), sd 39.96 (19–71), 13.13 37.12 (19–53), 9.64 -2.84 2.93 9.53 0.97 0.33
Ethnicity
Asian (%) 1 (1.8) 0 (0) 0.11
Black (%) 7 (12.5) 5 (29.4)
White (%) 42 (75) 11 (64.7)
Mixed (%) 5 (8.9) 0 (0)
Other (%) 0 (0) 1 (5.9)
Mean diary headache days (sd) 11.3 (7.59) 13.35 (7.96) 2.05 -1.98 2.94 -0.94 0.35
Mean number of days rescue
medication used in diary month (sd)
6.46 (5.44) 8.38 (5.86) 1.92 -1.87 1.74 -1.20 0.23
MIDAS, mean score (sd) 54.46 (45.64) 71.82 (44.06) 17.37 -16.98 10.81 -1.41 0.16
HIT-6, mean score (sd) 66.20 (5.50) 66.35 (3.98) 0.15 -0.11 2.63 -0.12 0.90
HADS-Anxiety, mean score (sd) 8.29 (3.91) 9.47 (3.54) 1.18 -1.15 1.12 -1.17 0.24
HADS-Depression, mean score (sd) 5.61 (4.07) 6.24 (3.29) 0.63 -0.60 1.58 -0.65 0.52
Brief-IPQ, mean score (sd) 51.70 (9.55) 53.41 (10.33) 1.71 -1.62 4.73 -0.61 0.55
n 1 missing data, MIDAS migraine disability assessment scale, HIT-6 headache impact test, HADS-A hospital anxiety and depression scale,
Anxiety subscale, HADS-D hospital anxiety and depression scale, depression subscale, Brief-IPQ brief illness perceptions questionnaire
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may also be reduced in a future trial by patients receiving
treatment after final follow-up.
The present study has documented treatment session
attendance; however, measuring the degree to which par-
ticipants perform treatment-related behaviour and cognitive
skills in real life settings [31] and amount of practice com-
pleted by participants outside of the treatment sessions
would be valuable in documenting process measures that
may be related to outcome. It is valuable to not only docu-
ment treatment delivery but also receipt and enactment of
treatment by participants [31, 32]. These measures would
complement process measures included in the therapeutic
alliance scale developed during the current study.
Conclusion
Previous studies show CBT and relaxation can improve
headaches by 49 and 32 %, respectively [33]. Our pilot
trial has provided necessary data for sample size calcula-
tions for a future trial. It illustrates that a definitive trial of
self-guided CBT with relaxation treatment is feasible
within the context of the NHS in the UK. Small modifi-
cations to the protocol, as described above, will enhance
the rigour of a future definitive trial.
Article highlights
• Studies show minimal contact CBT and relaxation
treatments for headache are equally effective.
• This is the first randomised controlled pilot study com-
paring a combination of a brief guided CBT and
relaxation to standard medical care (SMC), in the UK,
publicly funded context.
• Findings show adequate recruitment and good treat-
ment adherence.
• A definitive trial of self-guided CBT with relaxation
treatment is feasible within the context of the UK NHS.
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MIDAS migraine disability assessment scale, HIT-6 headache impact test, HADS-A hospital anxiety and depression scale, Anxiety subscale,
HADS-D hospital anxiety and depression scale, Depression subscale, Brief-IPQ brief illness perceptions questionnaire
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